Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Edison’s most frequently asked questions – Basilea Pharmaceutica

Edison’s most frequently asked questions – Basilea Pharmaceutica

Basilea Pharmaceutica — 9 videos in collection

More on this equity

Basilea Pharmaceutica (SIX:BSLN) is a commercial-stage biopharmaceutical R&D company focused on treating infectious diseases. Its core marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). The company continues to innovate to address unmet medical needs, leveraging management’s strong expertise in antifungals and antibiotics.

In this video, Basilea’s chief executive officer, David Veitch, and chief financial officer, Adesh Kaul, provide a brief introduction while addressing a few frequently asked questions.

Edison will be hosting the Basilea team in San Francisco for Healthcare Week on January 8-10, 2024. To request a 1×1 meeting with the Basilea team, please click here.

To learn more about Basilea, please access Edison’s content here.

< Previous
Next >

You may also be interested in these:

Healthcare

Interview with David Veitch, CEO of Basilea Pharmaceutica

Healthcare

Basilea Pharmaceutica – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free